


# SALSS 2013 PROFILES

---

*SPEAKERS, page 2-15*

*PRESENTING COMPANIES, page 16-20*

*RISING STARS, page 21-24*



**Speakers**  
**Thursday August 22<sup>nd</sup>**  
*In order of appearance*



**Dr. Anders Hamsten**  
**President, Karolinska Institutet**

Dr. Anders Hamsten is President of Karolinska Institutet since 2013. He is a member of the Nobel Assembly at Karolinska Institutet that awards the Nobel Prize in Physiology or Medicine and has in the past three years served on the Nobel Committee. Dr. Hamsten earned his medical and doctoral degrees at Karolinska Institutet. In 1997, he was appointed Professor of Cardiovascular Diseases, and he is since 1999 Senior Consultant Cardiologist at the Karolinska University Hospital. He has served as Chair of the Department of Medicine Solna, Karolinska Institutet in two periods and as Director of the Atherosclerosis Research Unit at the Department of Medicine for 20 years. He has authored almost 400 original articles, and his work has been cited >26,000 times (h-index: 86). Dr. Hamsten's research focus is in atherothrombosis, with the mission to unravel the etiology and pathophysiological mechanisms underlying atherosclerosis, arterial thrombosis and aneurysm formation. He is a principal investigator of the European PROCARDIS program on the search for new susceptibility genes underlying coronary heart disease, initiated with support from the European Commission in 1998. Professor Hamsten has served as member of the international evaluation panel of the Biocenter Oulu, University of Oulu, Finland and of the scientific boards of the Ragnar Söderberg Foundation and the Swedish Heart-Lung Foundation. He has also been serving as member of site visiting teams evaluating British Heart Foundation chairs and was elected Fellow of the Royal College of Physicians London in 2002.



**Dr. Kenneth R Chien**  
**Professor of Cardiology, Karolinska Institutet**

Dr. Kenneth Chien is an internationally recognized biologist, specializing in cardiovascular science, as well as a pioneer in developing new therapeutic strategies to prevent the onset and progression of heart failure. In 2012, Dr. Chien received a Presidential Call to a Professorship at Karolinska Institutet to start a new cardiovascular initiative with a major focus on regenerative cardiology. Previously, Dr. Chien was the Scientific Director of the Cardiovascular Research Center at Massachusetts General Hospital and Professor in the Department of Stem Cell and Regenerative Biology at Harvard University in Cambridge, where he also lead the University-wide Cardiovascular Stem Cell Program. While at Harvard, he was awarded the distinction of the first endowed chair of the Charles Addison & Elizabeth Ann Sanders Professor of Medicine. Prior to his MGH/HMS appointments, Dr. Chien directed the Institute for Molecular Medicine at the University of California at San Diego (UCSD) and was an adjunct professor of The Salk Institute. A graduate of Harvard University, Dr. Chien went on to earn his M.D. and Ph.D. from Temple University in Pennsylvania. After completing his internship, residency, and cardiology fellowship training at the University of Texas Southwestern Medical School in Dallas, he joined the faculty of the UCSD Departments of Medicine and Cardiology and the Center for Molecular Genetics. Subsequently, Dr. Chien became the Director of the UCSD Institute of Molecular Medicine and directed the joint UCSD-Salk Institute National Institutes of Health Molecular Medicine Training Program. Given his longstanding interest in training physician-scientists, he has served as an advisor/panel member of several private biomedical foundations, including the Doris Duke Charitable Foundation, and the Wellcome Trust. He also has served as a senior consultant and board member to several biotechnology and

large pharmas over the past decade, fostering collaborative ties between academia and the private sector. Dr. Chien was also heavily involved in the establishment of the Institute of Molecular Medicine at Peking University, currently the premier site for cardiovascular science in China. He has received several awards for his work, including the Pasarow Foundation Award, the Walter B. Cannon Award of the American Physiological Society, foreign-elect membership in the Norwegian Academy of Sciences and the Austrian Academy of Sciences, honorary professorships at Hong Kong University and Jiaotong University in Shanghai, and an honorary Doctorate of Science from the University of Edinburgh. He also has been active in biotechnology, serving as a senior advisor for Genentech/Roche and the SAB of the Pictet Biotechnology Fund for over a decade, and a Founder of Moderna Therapeutics based in Cambridge, Massachusetts.



**Dr. Vincent Giampapa**  
**Founder & CMO, CellHealth Institute**

Dr. Vincent Giampapa is a renowned cellular aging expert, surgeon, clinical researcher, and founder and Chief Medical Officer of CellHealth Institute. He has practiced clinical age-management medicine for over 20 years. Dr. Giampapa's research focuses on stem cell technologies and their clinical applications to improve the cellular aging process in order to enhance healthy lifespan and quality of life. As a result of his research, Dr. Giampapa has been awarded U.S. patents. He is also the author of six books on age management, including the first and only medical textbook on anti-aging medicine titled *The Principles and Practice of Anti-Aging Medicine for the Aesthetic Surgeon and Physician*. He earned his M.D. from Mt. Sinai Medical School and is a Fellow of the American College of Surgeons.



**Dr. Eugen Steiner**  
**Partner, HealthCap**

Dr. Eugen Steiner, M.D., Ph.D., is a partner of HealthCap, a leading European health care venture capital fund. Dr. Steiner is a serial entrepreneur and has served as Chief Executive Officer or Chairman of the Board of several biotechnology and biomedical companies, including Affibody, Biolipox, Biostratum, Calab Medical, Creative Peptides, Eureka Medical, Global Genomics, LTB4, PyroSequencing, Melacure Therapeutics, Nordic Vision Clinics, Optivy, and Visual Bioinformatics.



**Dr. Molly Stevens**  
**Professor of Biomedical Materials and Regenerative Medicine,**  
**Imperial College**

Dr. Molly Stevens is currently Professor of Biomedical Materials and Regenerative Medicine and the Research Director for Biomedical Material Sciences in the Institute of Biomedical Engineering at Imperial College. She joined Imperial in 2004 after a Postdoctoral training at the Massachusetts Institute of Technology. She has been recognized by numerous awards including the 2012 EU40 Award for top materials scientist in Europe under 40 and Technology Review's TR100, a compilation of the top young innovators worldwide. Her group is focused on both high quality fundamental science and translation for human health in the regenerative medicine and biosensing fields.



**Dr. Anders Haegerstrand**  
**General Manager, Newron**

Dr. Anders Haegerstrand, a Swedish resident, is the General Manager of NeuroNova AB and member of the Newron Group Management Team since Dec 2012. He joined NeuroNova in 2000, as CEO and first employee, and from 2004 as Chief Scientific Officer, focusing on the translation of the sNN0031 and sNN0029 programs from the discovery phase through pre-clinical and early clinical development. He received his training as M.D. at Karolinska Institutet in Stockholm from which he also received a Ph.D. degree and became associate professor in Neuroscience and where he established a lab with a focus on regenerative medicine and cell transplantation during 1990-1995. From 1995 to 1998 he was Project Leader for a US biotech collaboration and later VP of Discovery Research, both at Astra Pain Control (a part of the former Astra Group). This included responsibilities for programs ranging from early stage drug discovery to Phase I/II clinical trials. Following the merger between Astra and Zeneca in 1998, he was VP in the CNS and Pain Research Area Management team. Dr. Haegerstrand has pharmaceutical industry and biotech experience including small molecules, peptides, proteins, cells and medical devices. He has actively participated in several investigational new drug applications and as Principal Investigator for substantial non-dilutive research grants. He has published extensively, including app. 50 original papers and multiple posters and presentations.



**Dr. Karin Hehenberger**  
**CMO, Executive Vice President, Coronado Biosciences**

Karin Hehenberger, M.D., Ph.D., is the Chief Medical Officer, Executive Vice President at Coronado Biosciences, Inc. Most recently Dr. Hehenberger was the Senior Vice President, Strategic alliances at the JDRF, a large disease foundation, with a Mission to Prevent, Cure and better Treat type 1 Diabetes. In this role, she led and executed alliances between companies and academia. Prior to JDRF, Dr. Hehenberger served as Vice President, Metabolics Strategy and Business Development for Johnson & Johnson. Previously, Dr. Hehenberger was a consultant at McKinsey & Co., where she was a member of the healthcare practice focusing on projects ranging from product launch, acquisitions and R&D efficiencies. Dr. Hehenberger has been a buy-side analyst covering healthcare equities at two multi-billion dollar hedgefunds. She also has experience from the early-stage growth life sciences sector as a senior partner at a global venture capital firm based in Stockholm, Sweden. Dr. Hehenberger was a senior member of the Eyetech Pharmaceuticals management team prior to and during its IPO. She participated in the work leading to the approval and launch of Macugen, a product for age-related macular degeneration and diabetic retinopathy. Dr. Hehenberger holds M.D. and Ph.D. degrees from Karolinska Institutet in Stockholm, Sweden. She continued her research as a post-doctoral fellow at the Joslin Diabetes Center at Harvard Medical School. Dr. Hehenberger is Senior Advisor Biotechnology and Medical Innovation at the Department of Endocrinology and Surgery at Karolinska Institutet, on the Board of The Rolf Luft Foundation for Diabetes Research and The Core Sight Council associated with the Lighthouse foundation. Dr Hehenberger is a frequent presenter in her capacity as a well-known authority in diabetes research, business development, innovative financing and translational medicine.



**Ms. Susan L. Solomon**  
**CEO, the New York Stem Cell Foundation**

Ms. Susan L. Solomon is Chief Executive Officer and Co-Founder of The New York Stem Cell Foundation (NYSCF). Ms. Solomon serves on the Executive Committee of the Alliance for Regenerative Medicine is a founder and current Chair of NYAMR (New Yorkers for the Advancement of Medical Research), and is a Trustee of the Regional Plan Association. She is also on the Board of Directors for the Centre for Commercialization of Regenerative Medicine. In 2008, she received a New York State Women of Excellence Award from the Governor and the Triumph Award from the Brooke Ellison Foundation for her work in establishing NYSCF. In December 2012, she received the Stem Cell Action Leadership Award from the Genetics Policy Institute. Prior to founding NYSCF, Ms. Solomon was an attorney at Debevoise & Plimpton, served as founding Chief Executive Officer of Sothebys.com, Founder and President of Sony Worldwide Networks, and held executive positions at MacAndrews and Forbes Holdings and MMG Patricof and Co.



**Mr. Jürg Zürcher**  
**Partner & EMEA Biotechnology Leader, EY**

Jürg Zürcher's 25-year career with Ernst & Young has involved extensive audit and corporate finance experience with local and international Life Sciences clients (Actelion, Basilea, Esbotech, Evolva, GlyCart, GlycoVaxyn, Polyphor, Roche, Santhera Pharmaceuticals, Schwarz Pharma, Syngenta, Synthes and HBM BioVentures). In addition to serving as an audit partner to several venture capital companies, Jürg Zürcher is also active in the VC community, advising clients on fundraising opportunities and facilitating mergers. His rich understanding of the biotech market in the region was instrumental in providing the Swiss federal government with an in-depth analysis of the state of biotechnology in Switzerland and the launch of the 1st Swiss biotechnology report in March 2004. His experience of having worked with Ernst & Young in the United States has helped him to also successfully transition clients to International Reporting Standards (IFRS or U.S. GAAP). He is the partner responsible for the Ernst & Young biotech practice in EMEA.



**Dr. William A. Haseltine**  
**Chairman & President, ACCESS Health International**

Dr. William A. Haseltine Ph.D. has an active career in Science, Business and Philanthropy. He was a professor at Harvard Medical School and Harvard School of Public Health from 1976-1992 where he was founder and the chair of two academic research departments. He is well known for his pioneering work on cancer, HIV/AIDS and genomics. He has authored more than 200 manuscripts in peer-reviewed journals and is the author of several books including *"Affordable Excellence: The Singapore Healthcare System"*. He is the Founder of Human Genome Sciences, Inc. and served as the Chairman and CEO of the Company until 2004. He is also the Founder of several other successful biotechnology companies. Companies he has founded account for five drugs currently on the market including Benlysta and ABTRAX (Human Genome Sciences, Inc.), Velcade (Proscript/Leucocyte, Inc.), and Provenge (Dendreon, Inc.). Dr. Haseltine is currently Chairman and President of ACCESS Health International, Inc. ([www.accessh.org](http://www.accessh.org)) a foundation that supports access to affordable, high quality health services in low, middle and high income countries, and Chairman Haseltine Foundation for Science and the Arts that fosters a dialog between sciences and the arts. He is an advisor to several governments, biotechnology and pharmaceutical companies. He is a member of the Advisory Board of the IE University, Madrid, the Advisory Council for the Koch Institute of MIT and the Life Sciences Foundation, a member of the Advisory Board of the Council of Scientific and Industrial Research (India), a member of the Advisory Board of the Ragon Institute, the Rockefeller University Council, and the Advisory Board of the FXB Center for Health and Human Rights at the Harvard School of Public Health and the Advisory Board of the Council of Scientific and Industrial research (CSIR) of India, He is a Lifetime Governor of the New York Academy of Sciences and a member of the Board of AID for AIDS International, the Geoffrey Beene Alzheimer's Foundation and the Global Virus Network. He is an honorary member of the Board of Trustees of the Brookings Institution, a member of the Council on Foreign Relations. William Haseltine is also a supporter of the arts. He is a member of the Advisory Board of the Metropolitan Opera, New York, a member of the Chairman's Council of the Metropolitan Museum and a member of the Director's Council of the Museum of Modern Art, a member of the International Council of the Guggenheim Museum, a member of Board of Directors of the Young Concert Artists, Inc., the Youth Orchestra of the Americas, the American Friends of the Budapest Orchestra, and the China Arts Foundation.



**Dr. Brian K Kennedy**  
**CEO, Buck Institute of Aging**

Dr. Brian K Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of detecting, preventing and treating age-related conditions. These include Alzheimer's and Parkinson's diseases, cancer, stroke, diabetes and heart disease among others. He leads a team of 20 principal investigators at the Buck Institute - all of whom are involved in interdisciplinary research aimed at extending the healthy years of life. Kennedy earned his Ph.D. at the Massachusetts Institute of Technology. His pioneering work as a graduate student led to the discovery that Sirtuins (SIR2) - enzymes that coordinate cell stress and metabolism - are key factors in the aging process. His current work involves nutrient signaling pathways linked to dietary restriction with an emphasis of the TOR pathway. Scientists in the Kennedy lab study aging in several model organisms, including yeast, nematode worms, mice, and humans. His research involves an intensive focus that is unusual in the field - his work seeks to move discoveries from simple organisms into mammalian animal models as quickly as possible in order to develop new approaches to alleviate age-associated diseases in humans. Kennedy has published more than 100 manuscripts in prestigious journals including Science, Nature, Cell and the Proceedings of the National Academy of Sciences. He served on the National Institutes of Health Cellular Mechanisms of Aging and Development study section from 2006 to 2012, as well as on the grant review committee for the American Federation for Aging Research. He is co-Editor-in Chief of Aging Cell, and an Associate Editor for multiple journals. He is co-founder of Delos Pharmaceuticals and NuVita Animal Health Inc., is a co-author on aging research patents and serves as a consultant for Biotech and Pharmaceutical companies. He is actively involved in aging research in the Pacific Rim, which features the largest elderly population in the world. He is a visiting professor at the Aging Research Institute at Guangdong Medical College in China. He is also an Affiliate Professor in the Department of Biochemistry at the University of Washington, Seattle.



**Dr. Bengt Winblad**  
**Professor of Geriatrics, Karolinska Institutet**

Professor Bengt Winblad, M.D., Ph.D. has been involved in the field of dementia research for many years. After pre-clinical medical studies in Vienna, Austria, he became M.D. 1971 and took his Ph.D. in 1975 at Umeå University, Sweden, where he became a Docent in 1977 and Professor of Geriatric Medicine and Chief Physician in 1982. Since 1987, he is working in Stockholm, Sweden as Professor of Geriatric Medicine at Karolinska Institutet and is Chief Physician at Karolinska University in Huddinge. Professor Winblad is Director of KI-Alzheimer Disease Research Center (KI-ADRC) in Huddinge, as well as the Swedish Brain Power research network. He is co-chairing the European Alzheimer Disease Consortium (EADC) and is the PI of the European Union Joint Program on Neurodegenerative Disorders (JPND) project BIOMARKAPD. He chaired the Medical Scientific Advisory Panel of the Alzheimer Disease International (ADI) 2007-2013. Dr. Winblad's research interests are experimental and clinical Alzheimer research with a translational approach and focus on early diagnosis and treatment. He has been presented with a number of awards for his contribution to this research area, which have included the Swedish Society of Medicine Alzheimer Award, the Royal Swedish Academy of Medical Sciences Award, the Alois Alzheimer Award, the Swedish Society of Medicine Award and the IPA Recognition Award for Service to the Field of Psychogeriatrics. He has taken the initiative regarding pharmaceutical treatment of patients with severe Alzheimer's disease. Professor Winblad has been a tutor for more than 150 Ph.D. students and has published >1000 original publications in the field of gerontology/geriatrics/dementia research. Dr. Winblad, together with Khalid Iqbal and Henry Wisniewski, is the founder of the ICAD conferences (currently renamed AAIC). Dr. Winblad was in 2009 ranked the world's most prolific researcher in the Alzheimer field (J Alzheimer's Disease 2009).



**Dr. Jan M Lundberg**  
**EVP, Science and Technology & President, Lilly Research Laboratories**

Dr. Jan M. Lundberg, Ph.D. is Executive Vice President for Science and Technology and President of Lilly Research Laboratories (LRL). He is also a member of the company's executive committee. Dr. Lundberg joined Eli Lilly and Company January, 2010, with responsibility for Research and the Development Center of Excellence at Lilly. Prior to assuming his position at Lilly, Dr. Lundberg served as Global Head of Discovery Research at AstraZeneca for ten years and was a member of the senior executive team. He was involved with numerous candidate drug nominations, development projects and support for marketed products. After his medical education and receiving his Ph.D., Dr. Lundberg served as Professor at the Department of Pharmacology, Karolinska Institutet, Stockholm, Sweden. Dr. Lundberg has authored over 500 publications of original articles in international peer-reviewed journals and is listed as one of the highly cited authors by the Institute for Scientific Information (ISI). His work has focused on cell signaling in integrated systems using multiple mediators (peptides, purines, and nitric oxide) with translational applications to nervous system, endocrine, inflammation and cardiovascular areas. This research has been highly recognized and has received several awards. He has also been appointed as Honorary Doctor at the Pharmaceutical Faculty, Uppsala University (2006). Dr. Lundberg is the co-founder of a biotech diagnostic company (Aerocrine AB). Dr. Lundberg has served on several committees which include Chairman, Ph.D. and post doc programme at Karolinska Institutet, Evaluation Committee for the Swedish Medical Research Council, Executive Advisory Board, the Swedish Medical Products Agency Registration of New Drugs (part of EMEA), and EFPIA Research head group generating the Innovative Medicines Initiative (IMI), a major public private partnership with the European Union. He serves on PhRMA's Science and Regulatory Committee and is on the board of Biotechnology Industry Organization (BIO) and BioCrossroads.



**Dr. Catarina R Dolsten**  
**Global Health Advisor & Director of International Programming,**  
**The What to Expect Foundation**

Dr. Catarina R Dolsten has for a long time been committed to Global Health issues and is currently the Medical Advisor for International Programming at *The What to Expect Foundation* (WTEF) NY. The WTEF is in the process of developing three separate prenatal care programs for Liberia, Brazil and Bangladesh. The overall project is financed through a grant from the U.S. State Department. Prior to WTEF, Dr Dolsten worked at the Millenium Villages Health Department at the Earth Insititute, Columbia University NY. She has worked at the Sahlgrenska Hospital and associated clinics in Sweden, and she is a health advisor for Pro Mujer, a South American NGO that works with micro financing and health care for women in need and for New Seed International, a NGO in Ghana that works with victims and orphans of HIV/Aids. Additionally, she worked as a financial controller at John Deere and Akerlund & Rausing. Dr. Dolsten has a Bachelor in Business Administration and Economics as well as a Medical Degree, both from Lund University, Sweden. She grew up on the beautiful westcoast of Sweden and has been a resident in the NY area since 2004.





**Dr. Yuval Binur**  
**Managing Partner, Orchestra Medical Ventures**

Dr. Binur has over 26 years of worldwide venture capital experience. In 2000 he co-founded Accelerated Technologies - a differentiated investment firm focused on medical technologies. Prior to that, Dr. Binur has been a founding partner of Medica Venture Partners, an Israeli life sciences venture fund and prior to that a member of Adler & Co., a New York based venture capital firm. Dr. Binur has been a board member of over 40 venture-backed companies in pharmaceuticals, medical devices and technology. Among them are: PVT (now Edwards Lifesciences Sapien), superDimension (now owned by Covidien), Impella (now owned by Abiomed), Memory Pharmaceuticals (now owned by Roche), Pathway Medical (now owned by Bayer) and Oxigene Pharmaceuticals (now owned by Roche). He holds a Ph.D. degree in Physics and a B.Sc. degree in Electrical Engineering.



**Dr. Mouna Esmailzadeh**  
**Co-Founder & CEO, SciLife Clinic**

Dr. Mouna Esmailzadeh is the co-founder and CEO of SciLife Clinic, a clinic having a focus on preventing diseases, promoting longevity and increased healthy years of life. She is a Medical Doctor and holds a Ph.D. in Neuroscience from Stockholm Brain Institute at the prestigious Karolinska Institutet. In addition, she holds a Master's Degree in Philosophy. Dr. Esmailzadeh and her team at SciLife Clinic have gained a unique clinical experience in preventive healthcare by screening and supervising hundreds of individuals using the latest medical science and technology. Based on this experience, and by involvement in various interdisciplinary research studies that looks at the medical as well as socioeconomic benefits of a preventive approach, Dr. Esmailzadeh works actively with implementing a paradigm shift in today's healthcare, advocating prevention and early detection.



**Mr. Michael Kope**  
**President, CEO & Co-founder, SENS Research Foundation**

Mr. Michael Kope received his J.D. from the University of Michigan in 1990. He has served as the University of Michigan's Intellectual Property Counsel; as Director of Corporate Development for Aviron, and for MedImmune, Inc.; and as CEO and officer of a number of start-ups in the biotechnology space. He specializes in business development and consulting, and is widely experienced with biotechnology organizations. Mr. Kope has negotiated a broad range of business acquisition and partnership agreements, designed strategies for technology protection and promotion in many fields of research, and facilitated a number of successful startups.



**Dr. Andrew Hessel**  
**Distinguished Research Scientist, Synthetic Biology Expert Autodesk Bio/Nano Programmable Group**

Dr. Andrew Hessel is a futurist and catalyst in biological technologies, helping industry, academics, and authorities better understand the changes ahead in life science. He is also the co-founder of the Pink Army Cooperative, the world's first cooperative biotechnology company, which is aiming to make open source viral therapies for cancer. Trained in microbiology and genetics, Dr. Hessel has continually worked at the forefront of genomics, first to read and comprehend bacterial, human, and other genomes and more recently to write them. He believes the technology that makes this possible, called synthetic biology is revolutionary and that it will eventually surpass information technology (IT) as an economic engine and driver of societal change. He speaks widely on topics that include cells as living computers, life science as an emerging IT industry, and biological safety and security. Dr. Hessel is an advocate of open genetic engineering, believing that the field will increasingly resemble the software industry and give rise to open source, single purpose (app), and 'freemium' applications, and that it will be spearheaded by younger programmer-entrepreneurs. He is active in the iGEM and DIYbio (do-it-yourself) communities and frequently works with students and young entrepreneurs to help them be successful. Since 2009, Andrew has also been the co-chair of Bioinformatics and Biotechnology at the Singularity University, located at the NASA Research Park in Mountain View, California. There, he educates graduate students and executive participants on the disruptive shifts underway in life science and helps them become actively engaged in these changes. In November, 2011, he was appointed a fellow at the University of Ottawa, Institute for Science, Society, and Policy, focusing on how next-generation technologies shape society's future. Dr. Hessel has given dozens of invited talks related to synthetic biology, for groups that include Autodesk Inc., the FBI, the United Nations Biological Weapons Convention Implementation Support Unit, TEDx, Intel Inc., the New America Foundation, Alberta Innovates Technology Futures, the Oil Sands Leadership Initiative, and Statoil.

## **Speakers**

**Friday August 23<sup>rd</sup>**

*In order of appearance*



**Ms. Ulla Hamilton**  
**Vice Mayor of Stockholm & Chairman, Stockholm Business Region**

Ms. Ulla Hamilton is Vice Mayor for Enterprise, Traffic and Labour Market for the City of Stockholm and has an extensive background in politics as well as private sector. She has been a member of Stockholm City Council since 1995 and is a member of the Council of Mayors since 2006. She is a former Vice Mayor for Environment and Traffic and for Environment and Real Estate. Ulla Hamilton is also a former member of the Local Government Councils of Uppsala and Lund. She worked as a political expert at former Prime Minister Carl Bildt's chancellery 1991-1994 and she has been a consultant in PR and PA 1995-1999. Before becoming Vice Mayor she was Communication Manager at Svenskt Näringsliv (Confederation of Swedish Enterprise). Current assignments are: Member of the Stockholm City Council, Member of the Council of Mayors, Stockholm City Council Chair of the Labour Market Committee, Chair of Stockholm Business Region AB, Chair of the Traffic and Waste Management Committee, Representative of Stockholm County Association of Local Authorities – KSL, Member of the Crisis Management Board.



**Dr. Håkan Björklund**  
**Industry Executive, Avista Capital Partners & Chairman, Lundbeck**

Dr. Håkan Björklund is the former Chief Executive Officer of Nycomed, which was sold to Takeda Pharmaceuticals in September 2011 for 9.6 billion Euros. He joined Avista Capital Partners in October 2011. Dr. Björklund worked closely with the Avista team on the development of Nycomed prior to its sale to Takeda. Under Dr. Björklund's leadership, Nycomed grew from a predominantly Scandinavian business into a global pharmaceutical company with leading market positions in Europe, Russia/CIS, Brazil and Latin America. In 2006, Dr. Björklund led the integration of Altana Pharmaceutical, a German-based company that Nycomed purchased for 4.2 billion Euros. He was also instrumental in growing Nycomed in emerging markets, most recently through the acquisition of Guangdong Techpool Bio-Pharma Co., Ltd, a Chinese bio-pharmaceutical company, in 2010. Prior to Nycomed, Mr. Björklund was Regional Director at Astra (now AstraZeneca) and, earlier, President of Astra Draco. He is Chairman of the Board of Directors at Lundbeck A/S, a member of the Board of Directors of Coloplast A/S, Alere Inc. and Atos Medical AB. He was also a director at Danisco A/S until its recent acquisition by Dupont. He holds a Ph.D. in Neuroscience from Karolinska Institutet in Sweden.



**Dr. Stefan Larsson**  
**Partner & Managing Director, Boston Consulting Group**

Stefan is a Senior Partner of the Boston Consulting Group (BCG), the leader of its Global Health care Payer and provider business. He is a BCG Fellow focusing on Value based Health Care. Stefan joined BCG 1996 and has advised clients across the Health care industry covering strategy, organization and operational improvement projects. In BioPharma he has lead projects throughout the value chain from Preclinical and Clinical Development to Sales Force Effectiveness. He has lead over 50 Due diligence projects for European Private Equity clients. Stefan is an M.D. and Associate Professor from Karolinska Institutet. He did his Ph.D. research at Karolinska Institutet and Harvard Medical School and PostDoc at the MRC Human Genetics unit in Edinburgh and at the EMBL in Heidelberg.



**Dr. Johanna Adami**  
**Director & Head of Health Division, Swedish Governmental Agency for Innovation System**

Dr. Johanna Adami is Director and Head of Health Division at the Swedish Governmental Agency for Innovation Systems (VINNOVA). She also holds the position of professor in clinical epidemiology at Karolinska Institutet in Stockholm. Previously, she served as Medical Director of a medical technology company and has vast experience of practicing medicine, particularly in emergency care. She has a Ph.D. from Karolinska Institutet and, a M.D. from the University of Uppsala, as well as a Master of Public Health from Harvard University.



**Dr. Mathias Uhlén**  
**Managing Director, SciLifeLab**

Dr. Mathias Uhlén received his Ph.D. in chemistry at the KTH Royal Institute of Technology in Sweden. After a post-doc period at the EMBL in Heidelberg, Germany, he became Professor in microbiology at KTH Royal Institute of Technology in 1998. Dr. Uhlén has more than 350 publications in bioscience with focus on the development and use of affinity reagents in biotechnology and biomedicine. In the 80s, he was the first to describe the use of affinity tags for purification of proteins, a principle now widely used in bioscience. In the 90s, his group described a new strategy for DNA analysis called Pyrosequencing, a method that was further developed by 454/Roche into the first of a new generation of next generation sequencing methods. In the early 2000s, his group started an international effort in Sweden, India, China and South Korea, for the creation of a Human Protein Atlas with the aim to systematically map the human proteome with antibodies. Dr. Uhlén is member of the Royal Swedish Academy of Engineering Science (IVA), the Royal Swedish Academy of Science (KVA), the European Molecular Biology Organization (EMBO) and member of the Human Proteome Organization (HUPO) council. He was VP of KTH Royal Institute of Technology, responsible for external relations, from 1999 to 2001. Recently, he became the Director of a new center Science for Life Laboratory Stockholm for high-throughput bioscience. He has received numerous awards, including the Göran Gustavsson prize, the Gold Medal of the Royal Swedish Academy of Engineering Sciences, the Akzo Noble Award, the HUPO Distinguished Award, the KTH Great Prize, the ABRF award, the Scheele prize and the H.M. the King's Medal 8th size with the ribbon of the Order of Seraphim.



**Dr. Daniel Teper**  
**Founder & CEO, IMMUNE Pharmaceuticals**

Dr. Daniel Teper is the founder and CEO of IMMUNE Pharmaceuticals. Dr. Teper was the Managing Director for North America at Bionest Partners, a global Strategy Consulting firm advising pharmaceutical and public biotechnology companies and previously a New York based Partner at ISO Healthcare Consulting (now part of Monitor Group). Dr. Teper started his career at Sandoz (now Novartis) Global Headquarters in Basel and then in the United States where he had growing responsibilities in sales, marketing and new product development. He held senior executive positions in Europe, first at GSK as Head of Commercial Operations for Glaxo France and then as President and Chief Operating Officer of Laboratoires Delagrangé through the acquisition by Synthelabo (now part of Sanofi). He then became President at Global EURO RSCG Healthcare Worldwide, a leading marketing and communication group, where he help launch multiple industry blockbusters. Dr. Teper was a co-founder of Novagali (NYSE Euronext: NOVA), which was recently acquired by Japan's Santen. Dr. Teper holds a Doctor of Pharmacy degree (PharmD) from Paris XI University and an MBA from INSEAD.



**Mr. Adam Kostyál**  
**SVP, Corporate Client Group, NASDAQ OMX**

Mr. Adam Kostyál is the Senior Vice President of Corporate Client Group and head of European Listings for NASDAQ OMX. He is based in Stockholm. Mr. Kostyál has been with NASDAQ OMX for the past 11 years. He started his career at OMX as a Sales Director, and then became Head of the Strategic Initiative Groups in 2006. Most recently, Mr. Kostyál was VP of Market Technology Sales responsible for sales, account management, and business development for the European, Central and Eastern European regions. Prior to NASDAQ OMX, Mr. Kostyál held various positions with Enron, Cell Network and Bloomberg. He holds a BSc in Economics and Marketing from Vrije Universiteit de Bruxelles and speaks four languages including English, Swedish, Italian and French.



**Dr. Ulf Wiinberg**  
**President & CEO, Lundbeck**

Dr. Ulf Wiinberg has been President and CEO of H. Lundbeck A/S since 1 June 2008. Before joining Lundbeck, Dr. Wiinberg worked with the American medical corporation Wyeth / Lederle for 27 years where he held several different positions in sales and marketing over the years. When becoming President of Wyeth Consumer Healthcare in 2002, Dr. Wiinberg joined the Wyeth Corporate Management Committee. In 2005 he was appointed Senior Vice President of Wyeth Europe, and in 2008 he was appointed President of Wyeth Europe and Wyeth BioPharma holding strategic responsibility for all aspects of Wyeth's 8bn USD biopharma business. Dr. Wiinberg has significant experience in working with trade associations and has served as chairman of the World Self-Medication Industry Association. He is presently a board member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturer Association (IFPMA). Dr. Wiinberg is also a member of PhRMA (Pharmaceutical Research and Manufacturers of America). He serves as European representative on the UK MISG (Ministerial Industry Strategy Group) and in Denmark Dr. Wiinberg serves on the Industrial Policy Committee under the Confederation of Danish Industry.



**Mr. G. Steven Burrill**  
**Founder&CEO, Burrill & Company**

Mr. G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. Mr. Burrill founded and has been Chief Executive Officer of Burrill & Company, a venture capital and merchant banking firm, since 1994. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the field of biotechnology, life sciences, high technology, and manufacturing worldwide. He currently serves on the Boards of Directors of AliveCor (Chairman), Catalyst Biosciences, Depomed (NASDAQ: DEPO), NewBridge, Novadaq (NASDAQ: NVDQ), Targacept (NASDAQ: TRGT) and XDX. Previously he served as Chairman of the Boards of BioImagene, Abunda Nutrition and Pharmasset. In 2012 Mr. Burrill received the Richard Bolte, Sr. Award from the Chemical Heritage Foundation in Philadelphia for his biotechnology industry leadership worldwide. In 2011 he received a lifetime achievement award at Scrip Intelligence's annual Scrip Award ceremony in London. In 2008 he received both the BayBio Pantheon DiNA lifetime achievement award for his biotech leadership worldwide, and the Alan Cranston Living Legend Award for his central role in advancing biomedical research globally. In 2002 he was recognized as a biotech investment visionary by the Scientific American magazine (The Scientific American 50). In 1995 Mr. Burrill received BIO's "service award" for his global biotechnology leadership.



**Dr. Christina Åkerman**  
**Director General, Medical Products Agency (Läkemedelsverket)**

Since September 1, 2008 Dr. Åkerman's position is Director General at the Medical Products Agency, Sweden. She is a specialist in Clinical Pharmacology, has a Ph.D. in Clinical Physiology and an Executive MBA General Management from Stockholm School of Economics. Dr. Åkerman is a member of the board at Uppsala University and at Fouriertransform. During 2004–2006, Dr. Åkerman held the position as Marketing Company President of AstraZeneca in the Philippines. Since 1995, she has held senior positions as Project Manager, Medical Director and Marketing Director at Hässle Pharmaceuticals and AstraZeneca Sweden.



**Mr. Antonio Ponce**  
**Vice President, Elekta Latin America**

Mr. Antonio Ponce is the Vice President of region Latin America at Elekta since 2008. He is based in São Paulo, Brazil. Mr. Ponce has a previous as Managing Director of Varian Operation in South America between the years 1997 – 2008. He has also held the role as National Sales Manager of Baxter Health Care in Brazil for seven years, started in 1990. In the beginning of his career he was Sales Manager at Johnson & Johnson SA between the years 1991 – 1997.

Mr. Ponce has studied a marketing specialization in the area of communication science at the Francis Marion University. He has also studied five years law at the Centro Universitário das Faculdades the Metropolitanas.



**Mr. Alex Martin**  
**Senior Vice President, Corporate Development, Moksha8**

Mr. Alex Martin joined moksha8 in July 2011 after previously serving as CEO, CFO, and CBO of several dynamic biotech companies including Affectis Pharmaceuticals, Intercept Pharmaceuticals, and Bioxell S.p.A. He has raised over \$100m from private and institutional investors, completed two successful IPOs, acquired multiple pharmaceutical products, and signed 9-figure licensing deals. Mr. Martin began his career in 1989 at SmithKline Beecham Pharmaceuticals where he took on roles of increasing responsibility in sales, marketing, and business development. He later joined Novartis as Vice President, Global Business Development & Licensing where he was responsible for partnering their strategic assets. Mr. Martin has lived in seven countries, worked in five, and speaks four languages. He has a BA from Cornell University and an MBA from Harvard.



**Mr. Jaime Oliveira**  
**Director, ANVISA**

Mr. Jaime Oliveira is graduated in Law at the University of São Paulo. In 2001, he concluded his specialization in Environmental Law at the University of São Paulo Public Health College and Law College (University of São Paulo) and in 2002, he concluded a specialization in the field of Biosafety at the Federal University of Santa Catarina Department of Parasitology and Microbiology. In 2006, Mr. Oliveira obtained the title of Master in Biotechnological Law and Ethics (Regulation of Biotechnology and Bioethics) at the University of Sheffield, in the United Kingdom. He is currently a master's student at the University of São Paulo Public Health College. Mr. Oliveira has worked in the private sector as a lawyer until September 2007, in the field of Environmental Law and Health Regulation. Subsequently, he took a position as Substitute Assistant Head for Legal Affairs at the Executive Office of the Presidency, where he was successively responsible for the coordination of the Economic, Infrastructure, and Social areas of the Assistant Head of Legal Affairs. Jaime Oliveira was the Executive Secretary at the Brazilian Biosafety Council and the lead representative of the Executive Office of Presidency at the Interministerial Group of Intellectual Property and the Brazilian Biotechnology Committee. In 2011, he was appointed by the Brazilian Ministry of Health to take the position of Director at ANVISA's Board of Directors for a three years mandate from 01st April 2011 to 31 March 2014. There is a possibility of a second mandate as Director of ANVISA.

**Presenting Companies**  
**Thursday August 22<sup>nd</sup>**  
*11:00 a.m.*



**IMMUNE Pharmaceuticals Inc.**  
**U.S.**

IMMUNE Pharmaceuticals Inc. is a US Bio-pharmaceutical Company with R&D in Israel and focuses on the development of antibody therapeutics for cancer and inflammatory diseases. IMMUNE is publicly traded on the NASDAQ OMX Stockholm and the OTCQX in New York. IMMUNE lead phase II clinical candidate is bertilimumab a fully human antibody targeting eotaxin-1 a pro-inflammatory protein involved in Crohn's Disease and Ulcerative Colitis, Severe Asthma and Bullous Pemphigoid a rare auto-immune dermatological disease. Patients are selected for treatment based on eotaxin-1 levels, which could make bertilimumab one of the first personalized treatments for those diseases. IMMUNE is developing, in collaboration with the Hebrew University in Jerusalem, NanomAbs, which allow for targeted delivery of cancer drugs. Amiket is a phase III ready topical drug with fast track designation from the FDA for the treatment of chemotherapy induced neuropathic pain and is available for out-licensing.

For more information, please visit [www.indexpharmab.com](http://www.indexpharmab.com)



**CellHealth Institute**  
**U.S.**

CellHealth Institute (CHI) is a biotechnology company focused on cellular health that integrates breakthrough products and services with holistic lifestyle education. CHI collaborates with top-tier research universities and publicly traded biotech companies to offer fully integrated personalized health programs paired with scientific biomarker evaluations, a proprietary cell health supplement line, healthycell™ and advanced treatment through stem cell therapies. The organization is headquartered in New Jersey with an international regenerative medicine destination in Costa Rica set to open in 2014. CHI services and products allow people to take control of their own health at the most basic level – their cells.

For more information, please visit [www.cellhealth.com](http://www.cellhealth.com)





**TeraDiscoveries, Inc.**  
**SWEDEN**

TeraDiscoveries, Inc. designs new drugs and drug candidates and accelerates the process of drug discovery by substituting new innovative cloud computing techniques in place of certain older laboratory chemical methods. This reduces cost, decreases development time, and creates novel molecules with therapeutic value. We design drugs, out-license drugs and molecular libraries, and manage pre-competitive collaborations to drive these products to market more efficiently. TeraDiscoveries has a proprietary, accurate and efficient drug discovery platform based on ground-breaking life science computing methods that were originally developed in Duke University's chemistry department. The company's early funding came from Microsoft and it is located in Research Triangle Park NC. Designing new drugs that bind to a specified protein target requires finding the best molecule or peptide in a vast chemical space. TeraDiscoveries accelerates this process through our proprietary Inverse Design software and cloud computing. Our approach searches this space at unprecedented speed and at >90% accuracy compared to a 20% accuracy for competing methods, enabling selective drug design. Current targets include, but are not limited to Jak1, Jak2, Jak3, hdac8, Aurora A, Malaria, Parkinson's Disease, and PGP. We also do repurposing of existing drugs based on accurate computer matching. TeraDiscoveries is in the process of preemptively designing small, highly focused inhibitor libraries of small molecules and peptides for every known human protein.

For more information, please visit [www.teradiscoveries.com](http://www.teradiscoveries.com)

**Presenting Companies**  
**Thursday August 22<sup>nd</sup>**  
*3:00 p.m.*



**MentisCura**  
**ICELAND**

MentisCura, based in Reykjavik, Iceland, is a privately held diagnostic company serving clinicians and pharmaceutical clients with state-of-the-art services and technology to improve and accelerate the differential diagnosis of CNS disorders. The company currently operates the world's first fully automated EEG-based biomarker service for clinicians through its own clinic and remotely via electronically transmitted EEG recordings.

MentisCura's service is based on a decade in the design, development and clinical validation of powerful algorithm-based biomarkers by its team of clinical specialists and neurophysiological experts. From a five minute EEG recording, MentisCura provides a fast and reliable assessment of the likelihood that a patient is suffering from dementia and the type, including Alzheimer's disease and Lewy Body Dementia. The company will launch a new product for diagnosing ADHD in October of 2013.

MentisCura is a partner and board member of the Stockholm Brain Institute a consortium joining leading Swedish universities; Karolinska Institutet, Royal Institute of Technology and Stockholm University. MentisCura collaborates with leading universities including Institute for Ageing and Health, University of Newcastle and the University Hospital of Iceland.

For more information, please visit [www.mentiscura.com](http://www.mentiscura.com)



**ACCESS Health International  
U.S.**

ACCESS Health International is a not for profit foundation with the mission to improve access to high quality affordable health for people everywhere. It is think tank and consulting group that discovers and describes best practices in health care finance, health systems and medical processes. They share their knowledge through publications, conferences, innovation programs and workshops. They manage practitioner-to-practitioner training programs and serve as consultants to federal and state governments and to the private sector. ACCESS believes that through knowledge and close collaborations across sectors they can improve health systems in both emerging and advanced economies. ACCESS Health is a US foundation with offices in India, Singapore, the Philippines, Indonesia, Morocco, Sweden and the United States. ACCESS is supported by grants from foundations, government aid organizations, individuals, and consulting services. ACCESS Health Sweden is focused on aging. They are studying the Swedish elderly care system in-depth in order to understand the strengths and weaknesses of the system. Furthermore, they actively support the development of new solutions to improve the life of older persons. They believe that to be able to care for current and future generations of elderly, we need to engage people of all ages in the community as well as find new solutions and re-structure the way we provide care for elderly and chronically ill.

For more information, please visit [www.accessh.com](http://www.accessh.com)



**Orexo  
SWEDEN**

Orexo AB is an emerging specialty pharma company developing improved treatments using proprietary drug delivery technology. Orexo's expertise is within the area of reformulation technologies and especially sublingual formulations. The company has a portfolio of revenue generating EU and US approved products currently marketed under licence and Zubsolv® (buprenorphine and naloxone), approved July 3rd, 2013, to be launched in September for maintenance treatment of opioid dependence. in the US. Zubsolv® is a novel sublingual formulation of buprenorphine and naloxone using Orexo's extensive knowledge in sublingual technologies. Through application of its proprietary technologies Orexo has increased the bioavailability of the active ingredient, accelerated dissolve time, reduced tablet size and improved taste. In a comparative acceptability study 9 out of 10 participants choose Zubsolv® over the market leader Suboxone Film for a daily treatment. Zubsolv® has the potential to be the first new entrant into a growing USD 1.5 billion market, with more than five million patients suffering from opioid dependence and where a majority of patients are not adequately treated today. Market potential for Zubsolv® is at peak estimated at above USD 500 million in sales annually. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap.

For more information, please visit [www.orexo.com](http://www.orexo.com)

**Presenting Companies**  
**Friday August 23<sup>rd</sup>**  
*10:15 a.m.*



**Lundbeck A/S**  
**Denmark**

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life for people suffering from brain diseases. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at diseases such as depression and anxiety, psychotic diseases, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases. The company was founded by Hans Lundbeck as a trading company in 1915. Since then the company has evolved and grown dramatically. Lundbeck employs approximately 5800 people worldwide, 2,000 of whom are based in Denmark. We have employees in 57 countries, and our products are registered in more than 100 countries. Lundbeck is one of Denmark's most research-intensive enterprises. We employ more than 1,200 highly-trained specialists in our research and development units. Each year, Lundbeck ploughs back around 20% of its revenue into research and development of new pharmaceuticals to improve treatment options for the millions of people around the world suffering from brain diseases. Lundbeck markets a number of different pharmaceuticals for the treatment of brain diseases. The most recently launched compounds include: CipraleX/Lexapro® (depression), Ebixa® (Alzheimer's disease), Azilect® (Parkinson's disease), Xenazine® (chorea associated with Huntington's disease), Sabril® (epilepsy), Sycrest® (bipolar disorder), Onfi® (Lennox-Gastaut syndrome), Abilify Maintena™ (schizophrenia) and Selincro® (alcohol dependence).

For more information, please visit [www.lundbeck.com](http://www.lundbeck.com)



**ELEKTA**

**Elekta - Brazil**  
**Brazil**

Elekta Brazil is a Latin America subsidiary of the Swedish Elekta AB. Elekta Brazil was founded in June 2008 in the city of Sao Paulo. The company is composed by 86 employees which support the structures of Sales, Logistics, Installation, Education and Training, Service and Financing for all Elekta product lines in South and Central America.

For more information, please visit [www.elekta.com](http://www.elekta.com)



**Moksha8**  
**Brazil**

Moksha8 was founded in 2007 with the goal of becoming the leading pharmaceutical company in Latin America through the commercialization of high quality therapeutics. The company was founded by Simba Gill and Texas Pacific Group (TPG), one of the largest private equity firms in the world with \$50 billion under management. They have established full commercial operations in Brazil and Mexico and intend to expand into other high growth markets in Latin America. Moksha8 want to be the leading pharmaceutical company in Latin America and beyond with sustained high level growth. With expertise in corporate development, marketing, sales and operations allows for establishing strong partnerships with the world's leading pharmaceuticals companies. Quality and speed of execution is integral to the value provided to patients, healthcare providers and partners.

For more information, please visit [www.moksha8.com](http://www.moksha8.com)

**Rising stars**  
**Friday August 23<sup>rd</sup>**  
12:00 noon



**Corline**  
**SWEDEN**

Corline is a technology provider and integrates coating technology in partners' clinically approved products. Corline license out the right to use technology in specific fields and maintains production rights to reagents and acts as sole supplier to customers. Corline develops products together with partners, but maintains all coating development and mfct in-house. Corline offers a heparin coating technology CHS™ that significantly attenuates the inflammatory response and adds pro-healing functions, which results in an improved implant. CHS™ is one of two best-in-class heparin coating products on the market (other owned by Gore Medical) and is unique in that it can be used on all surfaces including living cells (not the case for Gore). Key selling points: clinical efficacy, easy to integrate, non-leaching, can be used to protect cells, pro-healing by promoting re-modelling of soft tissue repair devices.

For more information, please visit [www.corline.com](http://www.corline.com)



**InDex Pharmaceuticals**  
**SWEDEN**

InDex Pharmaceuticals is a immunology focused biopharmaceutical company. The most advanced product is Kappaproct which is currently in phase III- trial for treatment of severe refractory Ulcerative Colitis. Kappaproct was developed internally as a part of the companies patented platform which has also generated a portfolio of preclinical resources within immunology. The company also develops a Companion Diagnostic (CDx) to Kappaproct along with other diagnostical tools focused on irritable bowl syndrome (IBD) such as DiBiCol, diagnostic test that can discriminate between Crohn's disease and Ulcerative Colitis.

For more information, please visit [www.indexpharmab.com](http://www.indexpharmab.com)

The Innovation Office is a unit of the Swedish Medical Products Agency (MPA). We provide guidance regarding a broad spectrum of regulatory topics and how to navigate the regulatory resources available from the MPA. This includes the regulations governing clinical trials, medical devices and the approval of new drugs as well as how to access advice from our experts.

The MPA commands unique knowledge and expertise of the regulatory framework for the development of new drugs and medical products. Through greater visibility of the Innovation Office, they aim to increase awareness of the MPA's advisory resources, especially among small and medium-sized businesses and academic researchers.

For more information, please visit [www.mpa.se/innovationeng](http://www.mpa.se/innovationeng)

## **KERECIS**

**Kerecis**  
**ICELAND**

Kerecis is a medical device company focused on the treatment of tissue damage with Omega3-based regenerative technologies. Specifically, Kerecis is developing and producing a novel, patent-pending, tissue-regeneration material derived from fish skin to accelerate the healing of wounds and tissue reconstruction. The Kerecis material addresses the large, unmet need of the double-digit-growth biologics segment of markets such as; chronic-wounds, hernia repair, breast reconstruction and dura repair.

Products based on the Kerecis MariGen Omega3 technology are intact, decellularized fish skin sheets that have had all cells and antigenic materials removed. When the Kerecis reconstructive tissue matrix is applied to damaged tissue, it acts as a scaffold, recruiting the body's own cells. The matrix is revascularized, repopulated by the host's cells, and ultimately converted into living tissue.

Kerecis most advanced MariGen Omega3 product, is MariGen Wound, which is indicated for the management of chronic wounds, including diabetic, vascular and other hard-to-heal wounds. The product is CE marked and an FDA product approval is pending. Limited sales have already commenced in Iceland, UK and the Middle East. Patents are pending for the MariGen Omega3 technology in several countries around the world.

For more information, please visit [www.kerecis.com](http://www.kerecis.com)



**Medicon Village**  
**SWEDEN**

Medicon Village in Lund, Sweden, is an international life science hub for collaboration and innovation. Medicon Village is designed to foster unique and innovative collaborations among academy, innovation and the broad and diverse commercial life science industry and to speed the translation of promising new life science discoveries “from idea to market”.

Medicon Village offers a unique environment for life science organizations by integrating research, innovation and enterprise and thereby creating value for people’s health and well-being. Approximately 80 organizations are located at Medicon Village, and more than 800 employees work at the site.

For more information, please visit [www.mediconvillage.com](http://www.mediconvillage.com)



**Neurotez**  
**U.S.**

Neurotez, Inc. is a private corporation whose primary goal is to develop a Leptin product as a novel hormone replacement therapy for Alzheimer’s disease (AD) and/or as a preventative for those who are at risk.

Leptin, a naturally occurring human hormone associated with various metabolic effects, has a large number of receptors in memory centers of the brain. This protein is often present at decreased levels in patients suffering from Alzheimer’s disease, and cognitive deterioration in AD patients correlates strongly with a decline in circulating Leptin levels. The administration of Leptin inhibits both the production of amyloid beta ( $A\beta$ ) and also the phosphorylation of tau protein in a variety of in vitro and in vivo systems. Since  $A\beta$  and phospho-tau are widely viewed as two of the key factors in Alzheimer’s disease etiology, Leptin represents a highly attractive, multi-functional therapeutic approach. Perhaps most tellingly, Neurotez has demonstrated that the administration of Leptin significantly improves cognition across a variety of measures in transgenic mouse models of AD. Thus, a wide spectrum of preclinical findings strongly supports the likelihood that Leptin augmentation will effectively slow or stop the progression of AD and may even preclude or delay the onset of cognitive decline in pre-impairment individuals.

For more information, please visit [www.neurotez.com](http://www.neurotez.com)



**Sensidose**  
**SWEDEN**

Sensidose AB, a privately held Swedish drug delivery company, is developing a novel microtablet dosage form, using well known, out of patent, active ingredients. The Sensidose delivery concept is based upon being able to provide an individualized patient dosing. Hence "any" dose can be given at a number of predetermined times and thereby an individualized dosing schedule can be achieved. The concept is based on the use of microtablets, each containing an exact and subtherapeutic amount of the active substance. The microtablets are given by the help of a dosing device that is counting out individual numbers of microtablets. The dosing device simplifies and enables patient compliance and gives the patient a better drug profile in the blood, better usage of the drug, resulting in a better efficacy and less side effects. The first product to use this concept is Flexilev® for the treatment of Parkinson's disease. Product launch is planned for November 2013.

For more information, please visit [www.sensidose.com](http://www.sensidose.com)



**Spiber**  
**SWEDEN**

Spiber is a start-up biotechnology company. They see themselves as leaders in recombinant spider silk development and production. The company was founded in 2008. Its technologies are based on successful research on spider silk conducted at the Swedish University of Agricultural Sciences (SLU). Their primary goal is to develop and commercialize two state-of-the-art patented technologies: Spiber™ (Recombinant spider silk protein) and SolvNT (Solubility enhancement solution).

Their activities are focused on three main areas; Scale-up biomaterial production to industrial levels, develop their products to support the scientific and production needs of customers in their focus areas and license applications outside of their focus areas. Spiber is located in Uppsala, a university city and focal point of Sweden's number one life-science region. Their offices and laboratories are situated at the Biomedical Center (BMC) of Uppsala University. The company is privately owned.

For more information, please visit [www.spiber.com](http://www.spiber.com)